RxDoctor Payments Data

Ann-Marie Harris, APRN

Primary Care · Tampa, FLNPI 1104589027

Payments from drug & device makers

$1,573in general payments, 2019–2025

Across 77 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$578
  • AstraZeneca$324
  • Lilly USA, LLC$149
  • AbbVie$105
  • Bayer$82
  • Sanofi-aventis U.S. LLC$67
  • plus $268 from 9 others

What the payments were for

  • Food & beverage$1,573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,573 in reported general payments places this provider in the 75th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$19,885
Medicare patients
89
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$31,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,503
MounjaroTirzepatide18$17,775
EliquisApixaban15$14,388
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,943
Albuterol Sulfate HfaAlbuterol Sulfate49$1,460
Duloxetine Hcl29$958
Ibuprofen20$595
Omeprazole22$562
Fluticasone Propionate37$503
Potassium Chloride30$497
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med15$457
Gabapentin35$447
Rosuvastatin Calcium37$442
Meclizine Hcl22$423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$578$31,21628 claims
GSKTrelegy Ellipta$63$19,50314 claims
Lilly USA, LLCMounjaro$149$17,77518 claims
PfizerEliquis$67$14,38815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 725 primary care providers in Florida.

Other primary care in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →